Aspirin Reduces Risk of COVID-19 Death

According to researchers at the University of Maryland School of Medicine, aspirin use reduced the risk of death in hospitalized COVID-19 patients. The researchers found that patients who were receiving aspirin were less likely to be placed in the ICU or on a mechanical ventilator. These patients were more likely to survive COVID-19 than those who were not taking aspirin. The researchers conducted their study on the medical records of 412 COVID-19 patients who had an average age of 55 years and who were hospitalized due to the complication of COVID-19. About a quarter of patients were receiving low-dose aspirin (usually 81mg) before they were admitted or following admission to manage their cardiovascular disease.

The study revealed that aspirin use was associated with a 47% decrease in the risk of mortality, a 43% decrease in the risk of ICU admission, and a 44% reduction in the risk of being put on a mechanical ventilator. The aspirin group also did not experience any significant increase in adverse events such as major bleeding. COVID-19 increases the risk of blood clots in the visceral organs and blood vessels. The researchers believe that the blood-thinning effects of the aspirin prevent micro clot formation. Further clinical trials are necessary to prove the results. If aspirin shows this effect on COVID-19, it would make aspirin the first widely available, OTC medication that reduces COVID-19-related mortality.

To know more about origin, virology of COVID-19, Click here

To know more about emerging themes in COVID-19, Click here

To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com

Want to set up an online consultation for your practice, Click here

Ref link: https://www.cathlabdigest.com/content/aspirin-use-reduces-risk-death-hospitalized-covid-19-patients

#Featured